Generic gadolinium-based contrast agents: the future?

Abstract

Get full access to this article

View all access options for this article.

References

Frenzel

Lengsfeld

Schirmer et al.

Stability of gadolinium based magnetic resonance imaging contrast agents in human serum at 37℃. Invest Radiol 2008; 43: 817–828.

Fretellier

Salhi

Schroeder

et al.

Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: Role of pharmaceutical formulation. Eur J Pharm Sciences 2015; 72: 46–56.

Haylor

Schroeder

Wagner

et al.

Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. Radiology 2012; 263: 107–116.

Idée

J-M

Fretellier

Robic

et al.

The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Crit Rev Toxicol 2014; 44: 895–913.

Pietsch

Jost

Frenzel

et al.

Efficacy and safety of lanthanoids as X-ray contrast agents. Eur J Radiol 2011; 80: 349–356.

Shellock

Spinazzi

. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. Am J Roentgenol 2008; 191: 1129–1139.

Sieber

Lengsfeld

Walter

et al.

Gadolinium based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 2008; 27: 955–962.

Soulez

Bloomgarden

Rofsky

et al.

Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3–5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. Am J Roentgenol 2015; 205: 469–478.

White

Gibby Tweedle

. Comparison of Gd (DTPA-BMA) (Omniscan) versus GD (HP-DO3A) (Prohance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41: 272–278.